Polydex Pharmaceuticals Ltd. Files OTC Market Disclosure Documents

TORONTO, Feb. 29, 2016 -- Polydex Pharmaceuticals Limited (OTC Pink:POLXF) announces the filing of all of the required disclosure statements in order to be considered as providing current information to the public. As a result OTC Markets has removed the visible icon of a “Stop Sign” and re-established the Company as OTC Pink – Current Information.

In recent years, the Company had opted to enact certain cost-saving measures by foregoing compliance with certain Qualifying Guidelines in regard to filing of financial statements, but has maintained a long tradition of providing timely disclosure of financial statements on the company website (www.Polydex.com). By complying with OTC regulations of financial statement filing, the company has now been upgraded from providing no information to providing current information.

“With our sustained sales strength and profitability, we felt that it was time to revive our good standing on the OTC Pink sheet platform,” says George Usher, President and CEO of the Company. “Our shareholders have always known that full financial reports are available on our website and we wanted to make sure that any potential newcomers recognize the company’s transparency upon their first visit to our OTC Pink stock quote page. The Company is now recognized as current, and we intend to keep it that way.”

The Company’s publicly traded shares continue to be quoted on the OTC Pink platform (www.otcmarkets.com/stock/POLXF/quote)

Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website: www.Polydex.com Twitter: @PolydexPOLXF

Note:  This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or similar words. Actual events or results may differ materially from the Company’s expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities. Other risk factors discussed in the Company’s financial reports may also affect the actual results achieved by the Company.

Contact:
Investor Relations:  North Arm Capital Services, Linda Hughes, 1-877-945-1621, [email protected]